CNSX:ASIA

Stock Analysis Report

Executive Summary

Asia Cannabis Corp., an early-entry international agra-technology corporation, focuses on providing proprietary organic hybridization technology in Asia.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Share Price & News

How has Asia Cannabis's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-30.0%

ASIA

2.9%

CA Biotechs

-0.2%

CA Market


1 Year Return

n/a

ASIA

-16.4%

CA Biotechs

1.1%

CA Market

Return vs Industry: Insufficient data to determine how ASIA performed against the Canadian Biotechs industry.

Return vs Market: Insufficient data to determine how ASIA performed against the Canadian Market.


Shareholder returns

ASIAIndustryMarket
7 Day-30.0%2.9%-0.2%
30 Day0%-14.2%-3.3%
90 Day-19.2%-16.7%-1.6%
1 Yearn/a-16.4%-16.4%4.6%1.1%
3 Yearn/a-16.3%-16.3%13.1%3.1%
5 Yearn/a16.2%16.2%24.7%6.7%

Price Volatility Vs. Market

How volatile is Asia Cannabis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Asia Cannabis undervalued compared to its fair value and its price relative to the market?

3.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate ASIA's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate ASIA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ASIA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ASIA is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate ASIA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ASIA is good value based on its PB Ratio (3.1x) compared to the CA Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Asia Cannabis forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Asia Cannabis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Asia Cannabis performed over the past 5 years?

21.5%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if ASIA's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare ASIA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ASIA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: ASIA has a negative Return on Equity (-56.04%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ASIA is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ASIA is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Asia Cannabis's financial position?


Financial Position Analysis

Short Term Liabilities: ASIA's short term assets (CA$1.3M) exceeds its short term liabilities (CA$65.8K)

Long Term Liabilities: ASIA has no long term liabilities


Debt to Equity History and Analysis

Debt Level: ASIA is debt free.

Reducing Debt: ASIA has not had any debt for past 5 years.


Balance Sheet

Inventory Level: ASIA has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ASIA's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ASIA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ASIA has sufficient cash runway for 2.094192 years if free cash flow continues to reduce at historical rates of -312.7% each year.


Next Steps

Dividend

What is Asia Cannabis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ASIA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ASIA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ASIA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ASIA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ASIA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Asia Cannabis's salary, the management and board of directors tenure and is there insider trading?

0.5yrs

Average management tenure


CEO

David Pinkman (62yo)

0.5yrs

Tenure

0

Mr. David Edward Thomas Pinkman, BA, LLB has been Interim CEO, President and Corporate Secretary of Asia Cannabis Corp since April 30, 2019. He has been an Interim Chief Executive Officer of Synstream Ener ...


Management Age and Tenure

0.5yrs

Average Tenure

60yo

Average Age

Experienced Management: ASIA's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Age and Tenure

1.8yrs

Average Tenure

52.5yo

Average Age

Experienced Board: ASIA's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: ASIA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$3,94812 Aug 19
Johannes Kingma
EntityIndividual
Role
Member of the Board of Directors
Director
Shares42,000
Max PriceCA$0.094
BuyCA$130,80703 Jul 19
Inplanta
EntityCompany
Shares2,500,000
Max PriceCA$0.052

Ownership Breakdown


Management Team

  • Ken McKinnon (60yo)

    Consultant

    • Tenure: 0.4yrs
  • David Pinkman (62yo)

    CEO, President

    • Tenure: 0.5yrs
  • Vince Ghazar (47yo)

    CFO & Director

    • Tenure: 1.8yrs
    • Compensation: CA$34.14k

Board Members

  • Jo Kingma (56yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: CA$102.43k
  • David Pinkman (62yo)

    CEO, President

    • Tenure: 0.5yrs
  • Vince Ghazar (47yo)

    CFO & Director

    • Tenure: 1.8yrs
    • Compensation: CA$34.14k
  • Dwight Hudson

    Director

    • Tenure: 0.7yrs
  • Igor Kovalchuk (49yo)

    Director

    • Tenure: 1.5yrs

Company Information

Asia Cannabis Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Asia Cannabis Corp.
  • Ticker: ASIA
  • Exchange: CNSX
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$3.806m
  • Shares outstanding: 36.25m
  • Website: https://asiacannabiscorp.com

Location

  • Asia Cannabis Corp.
  • 1015 – 4th Street S.W.
  • Suite 730
  • Calgary
  • Alberta
  • T2R 1J4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ASIACNSX (Canadian National Stock Exchange)YesCommon SharesCACADJan 2019

Biography

Asia Cannabis Corp., an early-entry international agra-technology corporation, focuses on providing proprietary organic hybridization technology in Asia. Its products are used in the planting, growth, and  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 00:45
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.